JP Morgan Upgrades Qiagen on Potential Organic Growth, QIAsymphony Ramp Up | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Citing expected organic growth and a continuing ramp up of QIAsymphony, investment bank JP Morgan today upgraded Qiagen to Overweight.

In a research note, analyst Tycho Peterson upgraded the firm from Neutral and estimated full-year 2012 revenues at $1.25 billion and adjusted earnings per share at $1.01. He maintained a December 2012 price target of $19.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.

Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.

Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.

In Science this week: new chromatin imaging approach, and more.